Equities research analysts expect Mediwound Ltd (NASDAQ:MDWD) to announce earnings of ($0.19) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Mediwound’s earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.20). Mediwound reported earnings of ($0.16) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 18.8%. The business is expected to announce its next quarterly earnings report on Thursday, November 15th.
According to Zacks, analysts expect that Mediwound will report full-year earnings of ($0.71) per share for the current year, with EPS estimates ranging from ($0.75) to ($0.64). For the next financial year, analysts forecast that the firm will post earnings of ($0.72) per share, with EPS estimates ranging from ($0.83) to ($0.65). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that cover Mediwound.
Mediwound (NASDAQ:MDWD) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.05. The company had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.96 million. Mediwound had a negative net margin of 783.30% and a negative return on equity of 210.90%.
NASDAQ MDWD opened at $6.49 on Friday. The firm has a market capitalization of $166.34 million, a price-to-earnings ratio of -10.47 and a beta of -0.13. Mediwound has a 52-week low of $3.56 and a 52-week high of $7.35.
Several large investors have recently added to or reduced their stakes in MDWD. Nexthera Capital LP bought a new position in shares of Mediwound during the 2nd quarter worth about $308,000. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in shares of Mediwound by 1.0% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,098,277 shares of the biopharmaceutical company’s stock worth $14,478,000 after acquiring an additional 21,559 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of Mediwound by 19.9% during the 1st quarter. Wells Fargo & Company MN now owns 121,323 shares of the biopharmaceutical company’s stock worth $631,000 after acquiring an additional 20,134 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of Mediwound by 10.4% during the 2nd quarter. Renaissance Technologies LLC now owns 130,500 shares of the biopharmaceutical company’s stock worth $900,000 after acquiring an additional 12,300 shares during the period. 32.13% of the stock is owned by institutional investors.
Mediwound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Featured Article: How Short Selling Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.